Top Markets
#1 Helium Helium +47.34%
#2 TENDIES TENDIES +43.82%
#3 Pons Pons +38.81%
#4 UnifAI Network UnifAI Network +18.28%
#5 Seeker Seeker +16.90%
#6 Songbird Songbird +15.77%
#7 Wrapped STX (Velar) Wrapped STX (Velar) +10.42%
#8 DAPPOS DAPPOS +10.15%
#9 OSK OSK +10.10%
#10 Bounce Bounce +9.81%
Coin of the day
Helium Helium
Ayarlar
Dil
TüRKçE
Para birimi
USD
Tema
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
Hisse Senetlerindeki Sıralama #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
Hisse Fiyatı
$9.50
Son senkronizasyon: 2025-01-08
Piyasa Değeri
$819.52M
Değişim (1 gün)
0.00%
Değişim (1 yıl)
0.00%
Ülke
US
Ticaret Poseida Therapeutics, Inc. (PSTX)

Kategori

Healthcare
Poseida Therapeutics, Inc. (PSTX) için P/S oranı
August 2026 itibarıyla P/S oranı TTM: 14.31
Poseida Therapeutics, Inc. şirketinin en son mali raporları ve hisse fiyatına göre, mevcut P/S oranı (TTM) 14.31'dir. 2022 yılının sonunda şirketin P/S oranı 2.92 idi.
Poseida Therapeutics, Inc. için P/S oranı geçmişi 2016 - 2026 arası
Her yılın sonunda P/S oranı
Yıl P/S Oranı Değiştir
2026 (TTM) 14.31 205.78%
2023 4.68 60.18%
2022 2.92 -99.98%
2021 13.55K 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 -100.00%
2017 204.33 119.21%
2016 93.21 0.00%
Benzer şirketler veya rakipler için P/S oranı
Şirket P/S Oranı P/S Oranı Farkı Ülke
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -28.95%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -29.22%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -79.37%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 -21.20%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH